Valens GroWorks CEO: Focused on the (Near) Future of the Cannabis Industry
Canada made history in October 2018 becoming the second country (after Uruguay) to legalize cannabis for adult-use.
The Canadian cannabis (r)evolution is not completed, however, as Health Canada is delaying the legalization of edibles, beverages, and other alternative delivery systems based on cannabis extracts for one year. With the widely recognized negative health effects of smoking, consumers are looking for more healthy and pleasant ways to access cannabis, both for recreational and medical purposes. As a result, there has been an influx of investment throughout the industry in research and development of extract-based products.
Valens GroWorks (CSE:VGW), based in the Okanagan region of British Columbia, is one of the leaders in the charge to develop attractive, brandable, high margin, and healthy products derived from cannabis. Holding three licenses from Health Canada and boasting some of the most advanced facilities in the market, Valens has been actively building the infrastructure and relationships to succeed both in Canada and internationally as cannabis-derived products take over the market.
Recent deals point the way
Valens received a license to cultivate and produce oils under the ACMPR in October. The company’s 25,000 square foot facility had previously been licensed under the Narcotics Control Regulations, and with the two sets of regulations merging as part of the new Cannabis Act, the company has all of the bases covered. Utilizing this facility to research, develop, and perfect its extraction services, Valens is now pursuing European Union GMP certification. These are the strictest standards in the world, and the anticipated certification in 2019 would position Valens for export to most any legalized market.
The company is concurrently building out what will eventually be a 400,000 square-foot greenhouse facility that would supply large volumes of cannabis grown specifically for Valens’ extracts. This in-house supply will allow Valens to develop and commercialize its own brands of products, giving the company complete control throughout the product life cycle.
Until that project is complete and licensed, Valens is pursuing deals like the one it recently announced with GTEC Holdings (TSXV:GTEC). Through an initial four year term, GTEC will ship bulk dried cannabis to Valens. Valens will then derive the requested extracts and oils, sending them back to GTEC for sale. Arrangements like this provide a revenue stream for Valens and offer other licensed producers an avenue to access Valens’ expertise to develop their own products. Future deals could go a step further in this direction, with Valens actually developing the final products for partners on a white label basis.
Valens has also entered into a multi-year extraction agreement with Canopy Growth (TSX:WEED) under which Valens will use its proprietary technology and methodologies to process Canopy’s whole flower and trim into high-grade cannabis resin. The first shipment for extraction processing is expected by the end of December 2018.
In the interview below, Valens GroWorks CEO Tyler Robson provided further insight into what the company is doing, the technology it is developing and what its next steps are in terms of international expansion.
Below is a transcript of our interview with Valens GroWorks CEO Tyler Robson. It has been edited for clarity and brevity.
Investing News Network: Please give our investor audience an overview of Valens and its vertically-integrated business model.
Valens GroWorks CEO Tyler Robson: Valens is a British Columbia-based cannabis company that focuses on proprietary extraction services for other licensed producers while bringing premium oil-derived products to the Canadian and international retail markets. We have been working diligently to perfect our trade, walking the walk before bringing everything to market. When looking at the trending sales in the United States, flower is on the decline and oils are aggressively rising in each legal state. We believe oils are the future of mass cannabis consumption and Valens has strategically positioned itself to be a key player in the extraction sector with the best equipment and an integral operations team. And I think it’s showing, with our preferred partners and clients being some of the best in the sector, committing to us for years to come before we even put a dollar on the books.
INN: What does it mean to be an ISO 17025-accredited testing laboratory, and a GMP compliant processing facility?
TP: Accreditation is very important to us, because we put consumer safety at the forefront of everything we do. Leading up to legalization, quality is something we knew would suffer as a result of the scaling of indoor and greenhouse cultivation facilities in an attempt to meet significantly larger demand levels in the Canadian market. ‘Growing pains’ is a very real term in this industry. Having said that, it’s extremely important to us at Valens that we continue to set the bar for producers and processors in the industry, to ensure the consumers are getting the products they want.
By being ISO 17025 accredited in our lab, it means we’re not only certified and know what to do, but we’re continuously audited to ensure we’re doing what we say we’re doing. When a product is tested at our facility, you can consider it to be the most accurate and transparent test results available in the sector. Our ISO 17025 accreditation also helps us to hold our industry peers to a standard of quality and transparency we believe the consumer deserves. We want to make industry players accountable for their product, and this is the best way we know how.
By being GMP compliant, it ensures our facilities are on par with some of the best pharmaceutical manufacturers in the world. That means that by having your product processed in our facility, or buying Valens branded products, whether for recreational purposes or medical, your product is handled with the utmost care throughout the entire process. Additionally, being EU GMP certified will allow us to be a player in the international market, by being able to export to essentially any country accepting legal cannabis in the world.
INN: What markets does Valens plan to serve through its products and strategic partnerships?
TR: Valens’ main focus, and what we’ve been so hard at work on, is the production of high-quality cannabis oil to service the future market of edibles, beverages and concentrates (including vape market, etc). As mentioned before, the demand is very steadily increasing in already-available markets, and I am certain Canada will follow closely behind this once these products come online. We will service these markets by providing unparalleled oil extraction and refining services to other companies, as well as creating Valens-branded products that will be sure to stand out against competitors for a variety of reasons.
INN: Please tell us about the SōRSE™ technology. What does it mean for Valens to have access to this via its partnership with Tarukino holdings?
TR: This is a huge opportunity for Valens, as well as for the emerging Canadian ingestibles market (edibles and beverages). Our exclusive agreement to bring Tarukino’s SōRSE™ technology to Canada is a game changer.
SōRSE™ is essentially an emulsion technology that breaks down cannabis oil into protected molecules while making it completely water soluble. When you put oil into water, it doesn’t mix, right? What this technology does is preserve all of the extracted compounds that make up the oil, but formulate it to mix effectively in water. So, much like adding food coloring to water and shaking it up, products using SōRSE™ will be completely homogenous in nature.
What a lot of people don’t understand is that when you ingest cannabis in edible form, your bioavailability (how your body receives the cannabis and its overall effect on you) is so volatile that it cannot be consistently applied. So a lot of people have a hard time trusting edibles. By using the SōRSE™ technology, that bioavailability is significantly increased, meaning our products require less cannabis input (minimizing cost as this is the highest input cost) and users get a much better and more consistent experience. The onset is accelerated from 30 minutes to two hours to just 15 minutes and the offset is decelerated. Usually edibles can last up to 5 hours causing panic in users, but with the SōRSE™ technology the high is limited to 1-2 hours. This allows users to have multiple drinks in one night while trusting the effects of that drink, much like users use alcoholic beverages.
The top selling cannabis-infused beverage in Washington state is Tarukino’s Happy Apple cider. The consumer update of SōRSE™ has already been proven in the market, so the product really speaks for itself. Beyond the IP technology, we also have exclusive rights to Tarukino’s line of cannabis beverages, and we’re very excited to introduce these proven products to the Canadian market.
INN: How is Valens developing an international footprint? Has there been any shift in thinking after seeing the deficit of product in Canada?
TR: Valens is looking internationally for a variety of reasons. Collaborative minds are a winning approach here at Valens, and for that reason, we are working closely with countries like Australia to bring their markets online. This includes service agreements and supply agreements to bring oils to the medical market, and to provide expertise in extraction as things start to grow, specifically with a partner of ours, MediGrowth Australia.
With regards to the shift in thinking, supply, and even more importantly, good quality supply, is in a massive shortage here in Canada. We are looking at markets like Colombia, specifically licensed producer Eticann, to import cannabis to the Canadian market once that avenue opens up. In the meantime, we will continue to complete the construction of Valens Farms while partnering with other quality licensed producers in our sector to ensure consumers receive the quality products they are after.
CEO interviews are part of investor education campaigns for clients advertising on the Investing News Network. Important news is contextualized by CEOs, and the resulting interviews are disseminated to the Investing News Network audience because they have value to market watchers.
The Investing News Network interviews a CEO for an understanding of their perspective on the company, the investment potential of the company and market news related to the company. The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities.
CANBUD Distribution Corp. (CSE:CBDX, FSE:CD0) leverages on timely and methodical execution of its revenue generating plan. It operates a trinitarian enterprise model in the plant-based protein, psychedelic pharmaceutical and non-psychedelic nutraceutical, and hemp cannabinoids (CBD) spaces. (www.canbudcorp.com).
The company’s vision and mission is to become a world leader in science and technological innovations through plant and mushroom-based disruptive wellness and environmental solutions.
Canbud Distribution
MISSISSAUGA, Ontario TheNewswire – April 19, 2021 Sire Bioscience Inc. (CSE:SIRE) (OTC:BLLXF) (FSE:BR1B) (CNSX:SIRE.CN) (“ SIRE ” or the “ Company ”) is pleased to announce that, in addition to Purple K, Canada’s top selling creatine pills, the Company’s wholly owned subsidiary, Fusion Nutrition Inc. (“ Fusion ”) in the coming 12 weeks will be launching 3 new creatine products:
-
– Purple K powder
– Purple K PURE capsule
– Purple K PURE powder
Brian Polla, CEO, COO and a director of the Company commented: “ For the first time under new management Fusion is shipping and selling products directly from the United States. This presents us with a significant potential new client base. This is the first country that we have opened, outside of Canada. Based on the market research we have conducted; we expect strong success with the launch of these new products”.
The Canadian Securities Exchange (“CSE”) has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
About Sire Bioscience
SIRE is headquartered in Mississauga, Ontario, and is managed by a group of successful entrepreneurs who have extensive experience in the areas of consumer-packaged goods, manufacturing, logistics, and distribution. SIRE is a CPG life science company focused on the plant-based foods and supplements industry.
For additional information contact:
Sire Bioscience Inc.
Website: sirebioscience.com
Socials: @sirebioscience
Forward‐Looking Information Cautionary Statement
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Forward-looking statements may be identified by statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Forward-looking statements herein include, but are not limited to, statements expectations of management’s focus on and growth expectations of the Fusion product lines and the Company’s business and strategic plans. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. SIRE undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of SIRE, its securities, or financial or operating results (as applicable). Although SIRE believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond SIRE’s control, including the risk factors discussed in SIRE’s Listing Statement dated August 22, 2019 which is available on SIRE’s SEDAR profile at www.sedar.com . The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. SIRE disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Copyright (c) 2021 TheNewswire – All rights reserved.
News Provided by TheNewsWire via QuoteMedia
Sire Biosciences
BevCanna’s Naturo Group Signs Exclusive Distribution Agreement for TRACE in Japan and the Philippines
Market entry will address pent-up demand in the Japanese & Philippine markets for TRACE proprietary plant-based mineral formulation and wellness-focused products
Emerging leader in innovative health and wellness beverages and natural products, BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) (“ BevCanna ” or the “ Company ”) announces today that has entered into an exclusive sales agency distribution agreement with Yokohama-based Mirai Marketing Inc. (“Mirai”) to bring Naturo Group’s TRACE proprietary plant-based mineral consumer products to Mirai’s extensive Japanese and Philippine sales and distribution networks.
Mirai will assist BevCanna with their entry into the new markets, providing connections to established companies with robust distribution networks. Mirai has significant knowledge and relationships in the wellness products market and has facilitated over $100M in transactions with some of Asia’s largest trading companies and retail chains. The well-known distributor will leverage this extensive experience to rapidly scale the TRACE brand throughout the territories. The initial term of the agreement will be two years, with exclusivity subject to a minimum net revenue of C$1.0M over the course of the term and incentives to reach over C$5.0M during the term.
“We’re in active discussions with a number of distributors, wholesalers, trading companies and retailers to determine the best fit for the TRACE brand in the Japanese and Philippine markets,” said Melise Panetta, President of BevCanna. “Japanese consumers in particular are very health-conscious, and prospective partners have confirmed that the wellness benefits of our TRACE portfolio will be very appealing to this demographic.”
With over 40 years of experience working with some of Asia’s largest corporations, Mirai Marketing was founded by a team of Canadian and Japanese principals who have extensive experience in international sales, management and project development in a range of industries. Mirai is actively focusing on expanding sales of Naturo Group’s beverage and natural wellness products throughout Asia.
“We’re very excited to represent the TRACE products in the Japanese and Philippine marketplaces,” said Hideaki Sakuma, COO of Mirai. “We’ve seen an incredible growth in the demand for wellness-focused products by Asian consumers in recent years and an eagerness to participate in the evolution of health products. The TRACE line is certain to be a strong performer in this emerging market.”
About BevCanna Enterprises Inc.
BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) is a diversified health & wellness, beverage and natural products company. BevCanna develops and manufactures a range of plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients.
With decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale, the team demonstrates an expertise unmatched in the nutraceutical and cannabis-infused beverage categories. Based in British Columbia, Canada, BevCanna owns a pristine alkaline spring water aquifer and a world–class 40,000–square–foot, HACCP certified manufacturing facility, with a bottling capacity of up to 210M bottles annually. BevCanna’s extensive distribution network includes more than 3,000 points of retail distribution through its market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network, and a partnership with #1 U.S. cannabis beverage company Keef Brands .
On behalf of the Board of Directors:
John Campbell, Chief Financial Officer and Chief Strategy Officer
Director, BevCanna Enterprises Inc.
Disclaimer for Forward-Looking Information
This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding: the Company’s agreement with Mirai, including the potential benefits thereof; the Japanese market for TRACE products and that the Company’s products will be very appealing to Japanese consumers; that there has been incredible growth in the demand for wellness-focused products by Japanese consumers in recent years and an eagerness to participate in the evolution of health products; that the TRACE line is certain to be a strong performer in this emerging market; and other statements regarding the business plans of the Company. The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements.
Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include, among other things: general market conditions; changes to consumer preferences; volatility of commodity prices; future legislative, tax and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the inability to implement business strategies; competition; currency and interest rate fluctuations; inability to successfully negotiate and enter into commercial arrangements with other parties; and other factors beyond the control of the Company and its commercial partners. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law, and the Company does not assume any liability for disclosure relating to any other company mentioned herein.
Stock Option Grant
In connection with the sales agency distribution agreement with Mirai, the Company has granted (the “Grant”) an aggregate of 1,000,000 stock options (each, an “Option”) to purchase up to 1,000,000 common shares of the Company to Mirai. The Options granted vest upon the achievement of certain sales performance milestones and are exercisable for a period of 25 months from the date of Grant at a price of $1.50 per common share.
None of the securities acquired in the Grant will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005225/en/
For media enquiries or interviews:
Wynn Theriault, Thirty Dash Communications Inc.
416-710-3370
wynn@thirtydash.ca
For investor enquiries:
Bryce Allen, BevCanna Enterprises Inc.
778-766-3744
bryce@bevcanna.com
News Provided by Business Wire via QuoteMedia
BevCanna
Further to its press release dated April 12, 2021, Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or “ Ayurcann ”), is pleased to announce that it has oversubscribed and upsized its non-brokered private placement (the “Offering”) due to strong investor demand. The Company now anticipates that the Offering will be completed for gross proceeds of not less than $550,000.00, consisting of not less than 2,910,053 units (“Units”) at a price of $0.189 per Unit. Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one Common Share purchase warrant (a “Warrant”). Each Warrant is exercisable to acquire one Common Share at an exercise price of C$0.38 per Common Share for a period of 36 months from the date of closing of the Offering (the “Closing Date”), scheduled for April 22, 2021. The Units will have a hold period of four months and one day from the date of issuance.
Ayurcann CEO Igal Sudman commented: “We are very pleased with the demand we are seeing for the Offering. The feedback we have received to date is showing that our business is resonating with investors. We’re looking forward to closing the offering and proceeding with the planned Phase 2 build out, which will help greatly increase our facility’s capacity.”
As previously stated, certain insiders of the Company may participate in the Offering. The Company may pay a commission in cash equal to 6% of the value of select proceeds raised under the Financing, specifically excluding any funds raised from insiders.
The Company will use the gross proceeds of the Offering for their Pickering facility Phase 2 expansion, which, when such expansion is complete, is estimated to increase the Company’s annual extraction capacity from 200,000 kgs to 300,000 kgs, and increase the fulfillment capabilities of cannabis 2.0 and 3.0 products from approximately 1 million units annually to approximately 2.5 million units annually.
For further information, please contact:
Igal Sudman, Chairman, Chief Executive Officer and Corporate Secretary
Ayurcann Holdings Corp.
Tel: 416-720-6264
Email: igal@xtrx.ca
Investor Relations:
Ryan Bilodeau
Tel: 416-910-1440
Email: ir@ayurcann.com
About Ayurcann Holdings Corp.:
Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada. Ayurcann is focused on becoming the partner of choice for leading Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing.
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward- looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements, including but not limited to statements relating to the Company’s expansion plans and future production capacity. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.
Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include, but are not limited to, failure to obtain regulatory approval, ability to increase production at the Company’s facilities, the continued availability of capital and financing, and general economic, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, Further, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. Public health crises, including the ongoing novel coronavirus (COVID-19) pandemic, could have significant economic and geopolitical impacts that may adversely affect the Company’s business, financial condition and/or results of operations. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.
News Provided by GlobeNewswire via QuoteMedia
Codebase Investee, Instacoin NFT App Completes Worldwide Testing Phase and Submission to Apple Store Platforms
UK InstaCoin APP Promises to Open NFTs up to the Masses through Social Media
Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is pleased to provide an update on its recent investment in InstaCoin Technologies Ltd., a newly formed UK entity
Following an extensive testing period, new NFT APP InstaCoin has announced a global submission to the Apple store platforms with imminent release. The APP which promises to simplify the creation of NFT assets from a user’s social media has gone through extensive scale and blockchain testing as well as creating full language compatibility with the Chinese markets and European block.
NFTs are the new and most popular way to sell digital content across the world. Up until now the focus has been on large value sales, InstaCoin APP promises to bring the creation and auction element to the everyday person.
Code has a strong track record with the founders of InstaCoin through the Company’s existing TRAD3R investment. Code is excited to expand their involvement with TRAD3R and InstaCoin, as both entities are taking an innovative approach within the blockchain ecosystem. Code has taken an early 50% equity position of InstaCoin who aims to democratize NFT’s rather than focus primarily on multi-million dollar individual components.
The InstaCoin APP is positioned as the world’s first self-serve social NFT platform. InstaCoin will allow users to connect their social profiles to the blockchain and create instant NFT tokens from their own content. Followers and fans connect in the open market for immediate sales.
InstaCoin Technologies Ltd., a newly formed UK entity, has no relationship with any other company or crypto exchange with similar names, including Instacoin Capital Inc.
About Codebase Ventures Inc.
Codebase Ventures Inc. seeks early-stage investments in emerging technology sectors, including the blockchain ecosystem and fintech. The Company identifies such opportunities and applies its relationships and capital to advance its interests.
For further information, please contact:
George Tsafalas – Ivy Lu
Investor Relations
Telephone: Toll-Free (877) 806-CODE (2633) or 1 (778) 806-5150
E-mail: IR@codebase.ventures
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management’s current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “predicts”, “intends”, “targets”, “aims”, “anticipates” or “believes” or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.
SOURCE: Codebase Ventures Inc.
View source version on accesswire.com:
https://www.accesswire.com/640877/Codebase-Investee-Instacoin-NFT-App-UK-Completes-Worldwide-Testing-Phase-and-Submission-to-Apple-Store-Platforms
News Provided by ACCESSWIRE via QuoteMedia